ADReCS

Pharmaceutical Information

Drug Name	Imatinib
Drug ID	BADD_D01136
Description	Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage	For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status	approved
ATC Code	L01EA01
DrugBank ID	DB00619
KEGG ID	D08066
MeSH ID	D000068877
PubChem ID	5291
TTD Drug ID	D0AZ3C
NDC Product Code	63850-4826; 68554-0034; 43598-345; 65162-795; 42292-044; 0378-2246; 43598-344; 51407-270; 0378-2245; 42292-043; 51407-269; 48087-0143; 65162-794
UNII	BKJ8M8G5HI
Synonyms	Imatinib Mesylate \| Mesylate, Imatinib \| Imatinib Methanesulfonate \| Methanesulfonate, Imatinib \| STI571 \| STI-571 \| STI 571 \| Gleevec \| Glivec \| ST 1571 \| ST1571 \| CGP 57148 \| CGP57148B \| CGP-57148 \| CGP57148 \| Imatinib \| Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide

Chemical Information

Molecular Formula	C29H31N7O
CAS Registry Number	152459-95-5
SMILES	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Malignant peritoneal neoplasm	16.13.04.005; 07.21.03.005	0.000112%		Not Available
Ovarian epithelial cancer	21.11.01.017; 16.12.04.006	0.000224%		Not Available
Glomerulosclerosis	20.05.03.008	0.000112%		Not Available
Leukaemia recurrent	16.01.03.005; 01.10.03.005	0.002037%		Not Available
Necrotising panniculitis	23.07.02.003; 10.01.03.043	0.000448%		Not Available
Dysplastic naevus	23.10.01.011; 16.26.01.011	0.000112%		Not Available
Metastatic squamous cell carcinoma	16.16.01.010	0.000112%		Not Available
Acute lymphocytic leukaemia recurrent	16.01.01.003; 01.10.01.003	0.002015%		Not Available
Multimorbidity	08.01.03.075	0.000112%		Not Available
Graft versus host disease in skin	23.07.04.025; 10.02.01.062; 12.02.09.031	0.000336%		Not Available
Necrotising retinitis	24.04.10.006; 06.04.06.012	0.000168%		Not Available
Clonal evolution	16.32.03.022	0.000112%		Not Available
Pelvic fluid collection	21.07.04.011; 07.07.01.009	0.000112%		Not Available
Oral cavity fistula	07.11.05.014	0.000168%
Intracardiac mass	24.01.05.010; 02.11.01.016	0.000414%		Not Available
Left atrial dilatation	02.04.02.025	0.000168%		Not Available
Apparent death	08.01.03.062	0.000168%		Not Available
Skin plaque	23.03.03.044	0.000504%		Not Available
Graft versus host disease in lung	12.02.09.030; 10.02.01.061; 22.01.01.021	0.000168%		Not Available
Oncologic complication	16.32.03.025	0.000224%		Not Available
Chronic myeloid leukaemia transformation	16.01.07.004; 01.10.07.004	0.001287%		Not Available
Tumour rupture	16.32.03.033	0.000224%		Not Available
Metastases to pelvis	16.22.02.021; 21.07.04.008	0.000168%		Not Available
Vulvovaginal rash	23.03.13.023; 21.08.02.018	0.000437%		Not Available
Spinal pain	17.10.01.020; 15.02.01.008; 08.01.08.030	0.000358%		Not Available
Dropped head syndrome	17.05.03.015; 15.05.06.002	0.000336%		Not Available
Preterm premature rupture of membranes	18.02.02.016	0.000168%		Not Available
Invasive ductal breast carcinoma	21.05.01.021; 16.10.01.013	0.000504%		Not Available
Diabetic metabolic decompensation	05.07.03.003; 14.07.03.003	0.000168%		Not Available
Arterial intramural haematoma	24.02.01.004; 12.02.01.018	0.000224%		Not Available

The 30th Page First Pre 30 31 32 Next Last Total 32 Pages